Rand Kenneth H, Beal Stacy G, Cherabuddi Kartikeya, Couturier Brianne, Lingenfelter Beth, Rindlisbacher Cory, Jones Jay, Houck Herbert J, Lessard Kylie J, Tremblay Elizabeth E
Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Department of Medicine, University of Florida, Gainesville, Florida, USA.
Open Forum Infect Dis. 2020 Nov 29;8(1):ofaa560. doi: 10.1093/ofid/ofaa560. eCollection 2021 Jan.
Microbiologic results are critical to optimal management of patients with lower respiratory tract infection, but standard methods may take several days. The multiplex polymerase chain reaction BioFire Pneumonia (PN) panel detects 15 common bacterial species semiquantitatively as copy number/mL, 8 viral species, and 7 resistance genes in about an hour within the clinical laboratory.
We tested 396 unique endotracheal or bronchoalveolar lavage specimens with the BioFire Pneumonia panel and compared the bacterial detections to conventional gram stain and culture results.
Of the 396 patients, 138 grew at least 1 bacterium that had a target on the PN panel, and 136/138 (98.6%) were detected by the panel. A total of 177 isolates were recovered in culture and the PN panel detected 174/177 (98.3%). A further 20% of patients had additional targets detected that were not found on standard culture (specificity 69%, positive predictive value 63%, and negative predictive value 98.9%). Copy number was strongly related to standard semiquantitative growth on plates reported by the laboratory (eg, 1+, 2+, 3+ growths) and was significantly higher in those specimens that grew a potential pathogen. Both higher copy number and bacterial detections found by the PN panel, but not found in culture, were strongly positively related to the level of white blood cells reported in the initial gram stain.
Higher copy number and bacterial detections by the PN panel are related to the host respiratory tract inflammatory response. If laboratories can achieve a rapid turnaround time, the PN panel should have a significant impact both on patient management and on antibiotic stewardship.
微生物学检测结果对于下呼吸道感染患者的最佳治疗管理至关重要,但标准方法可能需要数天时间。多重聚合酶链反应BioFire肺炎(PN)检测板可在临床实验室约一小时内半定量检测15种常见细菌种类(以拷贝数/毫升计)、8种病毒种类和7种耐药基因。
我们使用BioFire肺炎检测板对396份独特的气管内或支气管肺泡灌洗标本进行检测,并将细菌检测结果与传统革兰氏染色和培养结果进行比较。
在396例患者中,138例培养出至少一种在PN检测板上有靶点的细菌,检测板检测出其中136/138例(98.6%)。培养共获得177株分离菌,PN检测板检测出174/177株(98.3%)。另外20%的患者检测出了标准培养未发现的额外靶点(特异性69%,阳性预测值63%,阴性预测值98.9%)。拷贝数与实验室报告的平板上标准半定量生长情况密切相关(例如1+、2+、3+生长),在培养出潜在病原体的标本中拷贝数显著更高。PN检测板发现但培养未发现的较高拷贝数和细菌检测结果均与初始革兰氏染色报告的白细胞水平呈强正相关。
PN检测板检测出的较高拷贝数和细菌与宿主呼吸道炎症反应有关。如果实验室能够实现快速周转时间,PN检测板应会对患者管理和抗生素管理产生重大影响。